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In individuals with diverse cardiovascular risk factors, signalling stimulated by the AT1 receptor
for the vasopressor angiotensin II is sensitized by heterodimerization with the receptor for the
vasodepressor bradykinin, B2. Signal sensitization and receptor heterodimerization rely on
eﬃcient maturation of the B2 receptor protein. To assess functional features of that important
cardiovascular receptor system, we established an in vivo model by using immunodeﬁcient
NOD.Scid mice for the expansion of transfected cells under physiological conditions. Compared
to cultivated cells, the in vivo model strongly facilitated B2 receptor maturation and
heterodimerization. To elucidate the mechanisms underlying the enhancement of B2 receptor
protein maturation under in vivo conditions, we performed microarray gene expression proﬁling.
Microarray analysis revealed a more than 1.7-fold up-regulation of the chaperone calreticulin
upon in vivo cell expansion whereas other important members of the general chaperone
system were only marginally altered. Down regulation of calreticulin expression by RNA
interference conﬁrmed the importance of calreticulin for eﬃcient B2 receptor maturation under
in vivo conditions. Receptor proteins synthesized in the Nod.Scid cell expansion model were
functionally active and sensitive to drug treatment as exempliﬁed by treatment with the
AT1-speciﬁc antagonist losartan. Thus, we established a model system that can be used
to analyze functional features of proteins in vivo by expanding transfected cells in
immunodeﬁcient NOD.Scid mice.
Introduction
The major receptor for the vasoactive peptide hormone
angiotensin II, AT1, exerts an indispensable physiological
role in regulating vascular tone, ion and water homeostasis.
Apart from the important physiological role, the pathogenesis
of many cardiovascular disorders is characterized by a
dysregulation of the vital angiotensin II AT1 receptor
system leading to an exaggerated angiotensin II response.1
Cellular mechanisms accounting for the hyperactivity of the
angiotensin II system are therefore a major focus of
research aimed to improve strategies for the treatment of
cardiovascular disease.
Interaction of the bradykinin B2 receptor with the
angiotensin II AT1 receptor occurs in vivo and may contribute
to the hyperactivity of AT1-stimulated signal pathways under
pathological conditions of cardiovascular disorders.2–5 Signal
enhancement of the AT1 receptor by the B2 receptor relies
on the formation of AT1/B2 receptor heterodimers, which
requires disulﬁde-bond formation.3,4 The covalent association
of AT1 and B2 receptors seems to account for the enhanced
G-protein activation of AT1/B2 heterodimers relative to
dissociable receptors because covalently stabilized receptors
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Insight, innovation, integration
The AT1 receptor for the vasopressor angiotensin II is
involved in the pathophysiology of hypertension and cardio-
vascular disorders. Under various in vivo conditions, the AT1
response is sensitized by heterodimerization with the B2 receptor.
To analyze functional features of that important cardiovascular
receptor system, the study established a novel model that applies
immunodeﬁcient Nod.Scid mice for expansion of cultured cells
in vivo. Compared to conventional cell culture conditions,
receptor protein maturation and heterodimerization were
strongly facilitated by the novel model. In search for speciﬁc
features of the system, microarray gene expression proﬁling
revealed ﬁne-tuned alterations of the general chaperone system
that accounted for enhanced protein maturation and function in
the novel cell expansion model.
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constitute a cellular platform that is kinetically favoured
to interact with and activate heterotrimeric G-proteins.6,7
In agreement with this concept, signal enhancement of AT1
by the B2 receptor does not require the binding of bradykinin
to B2 because a mutated B2 receptor with aB700-fold reduced
aﬃnity for bradykinin is still capable of enhancing AT1
receptor-stimulated G-protein activation and signalling.3
Likewise, a B2 speciﬁc antagonist did not interfere with
the angiotensin II-mediated activation of AT1/B2 receptor
heterodimers.4 In contrast, a B2 receptor mutant deﬁcient in
G-protein activation did not enhance AT1 receptor-stimulated
signalling.3 These ﬁndings strongly suggest that the intra-
cellular receptor interface of B2 contacting the G-protein is
important for the signal enhancement of AT1.
In addition to signal enhancement, AT1/B2 heterodimerization
also alters the pathway of receptor internalization: The
dynamin-independent internalization of individual AT1 and
B2 receptors is switched to a dynamin-dependent internalization
pathway upon AT1/B2 heterodimerization.
3 Together these
data point to conformational changes of the intracellular
receptor interface upon heterodimerization, which may be
responsible for the speciﬁc features of AT1/B2 heterodimers
distinguishing receptor (hetero-)dimers from dissociable
receptors.6,7
The speciﬁc characteristics of AT1/B2 receptor heterodimers
were mainly deduced from receptors expressed under native
conditions.2–5 In contrast to native conditions, receptors
synthesized from transfected genes often contain large
quantities of immature protein prone to aggregation because
the endogenous chaperones assisting protein folding may be
limiting.8,9 To further analyze the functional features of
AT1/B2 receptor heterodimers and their potential (patho-)
physiological role, we established a novel model that
recapitulates protein folding under in vivo conditions by
expanding cultured cells in immunodeﬁcient NOD.Scid mice.
Materials and methods
Cultivation of cells and cell transfection
HEK293 cells were routinely grown in DMEM (450 mg/dl
glucose) supplemented with 10% (v/v) FCS, and kept in a
humidiﬁed 7.5% CO2/92.5% air atmosphere at 37 1C unless
otherwise indicated. Cells were transfected with Lipofectamine
Plus (Invitrogen). Plasmids encoding the human B2 and
AT1 receptor under control of the CMV promoter
(pcDNA3, Invitrogen) were used to generate clonal cell lines
with stable expression. To down regulate calreticulin
expression by RNA interference (RNAi), replated
NOD.Scid-expanded HEK293 cells were transfected with
stealth RNAi10 targeting the coding sequence of the human
calreticulin cDNA (nucleotides 59–83, RNAi-Calreticulin 1;
nucleotides 320–344, RNAi-Calreticulin2).10 Down regulation
of calreticulin was assessed by immunoblotting 40 h after
transfection. For RNA interference studies under in vivo
conditions, cell clones with RNA polymerase II promoter-
driven expression of a control micro-RNA or a micro-RNA
targeting calreticulin (nucleotides 324–344) were expanded in
NOD.Scid mice.11
Membrane preparation
Membranes of in vitro cultivated or in vivo expanded HEK293
cells were prepared by sucrose density gradient centrifugation
as described.3 Brieﬂy, the crude membrane pellet of in vitro
cultivated or in vivo expanded cells was prepared in 20 mM
Hepes, pH 7.4 containing 1 mM phenylmethylsulfonyl
ﬂuoride, 2 mM enalaprilate, 2 mM leupeptin, 1 mM bacitracin,
1 mM E64 and 1 mM phosphoramidon, layered onto a
gradient composed of 10–45% (w/v) sucrose and centrifuged
(100 000g, 4 1C, 4 h). The membrane fraction was collected,
diluted to a protein concentration of 1 mg ml1 and stored
at 80 1C for further use. Receptor-enriched membranes
contained usuallyB0.5–1 pmol B2 receptor/mg protein unless
otherwise indicated.
Antibodies used for immunoblotting and immunoﬂuorescence
The following antibodies were used for immunoblotting,
receptor immunoaﬃnity enrichment and immunoﬂuorescence:
aﬃnity-puriﬁed rabbit/rat anti-B2 receptor antibodies (raised
against an antigen corresponding to positions 28–60 of the
human B2 receptor sequence); aﬃnity-puriﬁed rabbit/rat anti-B2
receptor antibodies (raised against an antigen corresponding
to positions 356–391 of the human B2 receptor sequence);
aﬃnity-puriﬁed rabbit/rat anti-AT1 receptor antibodies (raised
against an antigen corresponding to positions 306–359 of the
human AT1 receptor sequence); aﬃnity-puriﬁed rabbit anti-AT2
receptor antibodies (raised against an antigen corresponding
to positions 320–349 of the human AT2 receptor sequence).
Speciﬁcity and cross-reactivity of the resulting antisera with
the respective protein was routinely monitored by immuno-
blotting and immunoﬂuorescence. All antibodies were
characterized in previous studies.3–6,11,12
Protein detection in immunoblot and co-enrichment of receptors
Immunoblotting was performed with membranes prepared by
sucrose density gradient centrifugation as described above
followed by partial enrichment.3 Proteins were dissolved in
SDS-sample buﬀer containing 2% SDS, 5% b-mercaptoethanol
and 6 M urea for 30 min at room temperature. Protein samples
were separated by SDS-PAGE under reducing conditions and
supplemented with urea followed by transfer to PVDF
membranes. Aﬃnity-puriﬁed antibodies or F(ab)2 fragments
of the respective antibodies pre-absorbed to human proteins
were used for detection of B2 or AT1 receptors. Bound anti-
body was visualized by pre-absorbed F(ab)2 fragments of
enzyme-coupled secondary antibodies or by enzyme-coupled
Protein A followed by enhanced chemiluminescence detection
(ECL plus).
For co-enrichment of AT1 and B2 receptors, membranes
of explanted HEK cells were solubilized with RIPA buﬀer
(including protease inhibitor cocktail), and subjected to
immunoaﬃnity chromatography by anti-AT1 receptor anti-
bodies using 0.1 ml immunoaﬃnity matrix (Aﬃgel 10; 15 mg
aﬃnity-puriﬁed antibodies per ml gel). After extensive
washing, proteins were eluted with 0.2 M glycine, pH 2.5,
neutralized, desalted, delipidated and precipitated.3 Eluted
proteins were dissolved and separated by urea-containing
SDS-PAGE under reducing conditions. Enriched AT1 and
210 | Integr. Biol., 2010, 2, 209–217 This journal is c The Royal Society of Chemistry 2010
Pu
bl
ish
ed
 o
n 
15
 M
ar
ch
 2
01
0 
on
 h
ttp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10
.10
39/
B9
225
92G
View Online
co-enriched B2 receptors were identiﬁed in immunoblot with
the respective anti-receptor antibodies.
Immunoﬂuorescence
Detection of receptors on NOD.Scid-expanded HEK293 cells
was performed with dispersed cells expanded in NOD.Scid
mice or cryosections (10 mm) of the isolated and frozen HEK
cell pellet obtained from 3 months-old NOD.Scid mice three
weeks after subcutaneous injection of 6–8  106 HEK293
cells/200 ml. For co-localization of AT1 and B2, aﬃnity-
puriﬁed rat anti-AT1 receptor antibodies and rabbit anti-B2
receptor antibodies were applied (dilution 1 : 4000), followed
by secondary antibodies labeled with Alexa Fluor 488 and
Alexa Fluor 546, respectively (Molecular Probes; dilution
1 : 5000). Sections and cells were imaged with a Leica
DMI6000 and a confocal laser microscope (Leica TCS SPE).
Microarray gene expression proﬁling
For microarray gene expression analysis, replated NOD.Scid-
expanded HEK293 cells, and in vitro cultivated HEK293 cells
(cultivated in DMEM supplemented with 10% FCS, and
450 mg/dl or 100 mg/dl glucose as indicated) were used. Total
RNA was isolated with the RNeasy Mini kit (Qiagen).
Procedures for cDNA synthesis, labeling and hybridization
were carried out according to the protocol of the manufacturer
(Aﬀymetrix GeneChip Expression Analysis Technical
Manual; Rev. 5). For hybridization, 15 mg of fragmented
cRNA were incubated with the chip (Aﬀymetrix GeneChip
Human genome U133 Plus 2.0 Array) in 200 ml of hybridization
solution in a Hybridization Oven 640 (Aﬀymetrix) at 45 1C for
16 h. GeneChips were then washed and stained using the
Aﬀymetrix Fluidics Station 450. Microarrays were scanned
with the Aﬀymetrix GeneChip Scanner 7G, and the signals
were processed using GCOS (v. 1.4, Aﬀymetrix). Gene expression
data are available at NCBI GEO database accession no
GSE15575 and GSE18739.
In vivo expansion of HEK293 cells in NOD.Scid mice
NOD.Scid mice (age 3 months) were injected subcutaneously
with 6–8  106 cells/200 ml PBS. For expansion in NOD.Scid
mice, HEK293 cell clones were used stably expressing the B2
receptor (HEK-B2) or co-expressing AT1 and B2 receptors
(HEK-AT1/B2). Three weeks after the injection, mice were
anesthetized, perfused intracardially with physiological
phosphate buﬀer, pH 7.2, and the expanded HEK293 cell
pellet was isolated and processed for further use. As indicated,
NOD.Scid mice were treated with or without the AT1-speciﬁc
antagonist, losartan, for three weeks (30 mg kg1 supplied in
drinking water).
Quantiﬁcation of cell-surface B2 receptors was performed
on dispersed, in vivo expanded HEK cells with 50 nM of
[125I]-labeled F(ab)2 fragments of aﬃnity-puriﬁed B2 receptor-
speciﬁc antibodies (B1 mCi) similarly as described.11
Animal experiments
All animal experiments were reviewed and approved by the
committees on animal research at the University of Hamburg
and Zurich, and were conducted in accordance with the NIH
guidelines.
Statistics
Unless otherwise stated, data are expressed as mean  S.E.
To determine signiﬁcance between two groups, we made
comparisons using the unpaired, two-tailed Student’s t-test.
P values o0.05 were considered signiﬁcant.
Results
Maturation of the bradykinin B2 receptor protein in cultivated
HEK293 cells depends on cell and culture conditions
AT1/B2 receptor heterodimerization relies on eﬃcient maturation
of the B2 receptor protein.
10 Over-expressing cells often
produce large amounts of immature protein because the
endogenous pool of chaperones may be limiting.8,9 In agreement
with those observations, HEK293 cells over-expressing the B2
receptor synthesized signiﬁcant amounts of an immature B2
receptor protein of 53  4 kDa in addition to the mature
protein of 67  5 kDa when cultivated in a standard cell
culture medium containing a glucose concentration of 450 mg/dl
(Fig. 1(a), lane 1; and ref. 10).
Glucose is known to down regulate the expression of several
chaperones.13 To enhance the maturation of the B2 protein, we
applied a medium with a ‘‘physiological’’ (low) glucose
concentration of 100 mg/dl. Compared to high glucose, the
low glucose medium led to the enhanced synthesis of the
mature B2 receptor protein of B67 kDa (Fig. 1(a), lane 2;
and ref. 10). These observations show that B2 receptor protein
maturation of in vitro cultivated cells is highly dependent on
cell and culture conditions.
Identiﬁcation of glucose-sensitive members of the general
chaperone system by microarray gene expression proﬁling
To determine the impact of cell culture conditions on the general
chaperone system of HEK293 cells, we performed microarray
gene expression proﬁling of HEK293 cells cultivated in medium
with high and low glucose, respectively. Microarray gene
expression proﬁling revealed a strong up-regulation of the
general chaperone system of HEK293 cells cultivated in low
glucose medium relative to high glucose (Fig. 1(b) and ref. 10).
The 14 glucose-sensitive members of the general chaperone
system of HEK293 cells are depicted in Fig. 1(b).
Immunoblot analysis conﬁrmed the increased expression of
important members of the general chaperone system under
low glucose as exempliﬁed for GRP78 and calreticulin
(Fig. 1(c)). As a control, b-actin expression levels were not
signiﬁcantly diﬀerent (Fig. 1(b and c)). Thus, maturation of a
prototypic membrane protein can be severely aﬀected by the
chosen glucose concentration of the culture medium because
several members of the general chaperone system are highly
glucose-sensitive.
In vivo expansion of HEK293 cells in NOD.Scid mice restores
an imbalanced chaperone system
As demonstrated above with a prototypical membrane
receptor, protein maturation can be extremely variable
This journal is c The Royal Society of Chemistry 2010 Integr. Biol., 2010, 2, 209–217 | 211
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depending on the selected culture conditions. To analyze
protein maturation in a more standardized environment, we
established an in vivo model. To this end we used immuno-
deﬁcient NOD.Scid mice for in vivo expansion of HEK293
cells. Cells were injected subcutaneously, and after three
weeks, the expanded HEK293 cell pellet was isolated from
NOD.Scid mice (Fig. 2(a)).
In contrast to conventional cell cultivation, in vivo expanded
cells are exposed to a tightly controlled physiological
environment. To validate the novel model, we analyzed
the general chaperone system by microarray gene expression
proﬁling. For our analysis, we selected those chaperones
that were highly regulated under in vitro cell culture conditions
(Fig. 2(b) versus Fig. 1(b)). Interestingly, the in vivo
model showed only subtle alterations of the general chaperone
system relative to in vitro cultured HEK293 cells (Fig. 2(b)).
A signiﬁcantly diﬀerent expression was only detected for
probe sets of four diﬀerent chaperones, i.e. glucose-regulated
protein (GRP78), protein disulﬁde isomerase (PDIA4),
HSEC61 and calreticulin (Fig. 2(b)). With a more than
1.7-fold increased expression, calreticulin showed the strongest
diﬀerence between in vivo and in vitro conditions. Thus, the
in vivo expansion of cells in NOD.Scid mice apparently
restored an imbalanced chaperone system without inducing
a massive up-regulation of the entire protein folding
machinery.
Expansion of HEK293 cells in NOD.Scid mice facilitates
B2 receptor protein maturation
The selective enhancement of calreticulin expression in the
established model system was intriguing because calreticulin is
known to be required for B2 receptor maturation, hetero-
dimerization and function.10,14 We therefore investigated
whether B2 receptor protein maturation was enhanced
upon in vivo cell expansion. HEK293 cell clones stably
expressing the B2 receptor were implanted subcutaneously into
NOD.Scid mice as detailed above. After three weeks, the
expanded cell pellets were isolated. Immunoﬂuorescence
conﬁrmed that the isolated cells consisted of expanded
HEK293 cells because the B2 receptor was only detected on
expanded HEK-B2 cells stably expressing the B2 receptor
whereas B2 receptors were not detected on expanded control
HEK-P3 cells lacking B2 receptor expression (Fig. 3(a)).
Fig. 1 Microarray gene expression proﬁling identiﬁes glucose-sensitive chaperones of HEK293 cells. (a) Immunoblot detection of the B2 receptor
(IB: anti-B2) on enriched membranes of HEK293 cells (expression ofB200 fmol B2/mg protein) cultivated in a medium with high (450 mg/dl) or
low (100 mg/dl) glucose revealed the mature (B2) and immature B2 receptor protein (immat. B2). (b) Microarray gene expression proﬁling of
HEK293 cells. Diﬀerentially expressed probe sets of low glucose-cultivated HEK293 cells relative to high glucose-cultivated HEK293 cells (x-fold
change; low/high gluc.; *P valuer0.01), ER localization and involvement in the general chaperone system are listed. If available, alternative probe
sets of the diﬀerentially expressed chaperones are also shown. Normalized signal intensity values are presented as heat map. Probe sets of beta actin
demonstrate integrity of biotin-labeled cRNAs used for gene chip hybridization (30/50 ratio: 1.17–1.36). (c) Immunoblot analysis controlling the
microarray data.
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Next, we determined the B2 receptor in immunoblot. In
agreement with the previous data (cf. Fig. 1(a)), the B2
receptor of conventionally cultivated HEK293 cells kept in a
high glucose medium appeared predominantly as an immature
form of 53  4 kDa. In contrast, upon in vivo expansion in
NOD.Scid mice, the B2 receptor of HEK293 cells was
synthesized as a mature form of 67  5 kDa (Fig. 3(b)).
Immunoblot detection of calreticulin conﬁrmed the micro-
array data showing that the in vivo expansion of cells in
NOD.Scid mice led to signiﬁcantly increased calreticulin
protein levels relative to in vitro cultivated HEK293 cells
(Fig. 3(b)). For comparison, changes in GRP78 expression
were only minor (Fig. 3(b)). As a control, maturation of the
B2-related angiotensin II AT2 receptor protein was not
diﬀerent before and after in vivo expansion (Fig. 3(c)).
Thus, the in vivo environment of NOD.Scid mice facilitated
maturation of the B2 receptor protein.
Involvement of calreticulin in B2 receptor maturation of in vivo
expanded cells
To analyze whether calreticulin was indeed involved in B2
receptor maturation, we down-regulated calreticulin
expression of in vivo expanded and replated HEK cells by
transfection of stealth RNAi. Down regulation of calreticulin
by RNA interference was conﬁrmed by immunoblot with
calreticulin-speciﬁc antibodies (Fig. 4(a), left panel). As a
control, transfection with an unrelated control RNAi duplex
did not aﬀect calreticulin protein levels (Fig. 4(a), left panel).
Concomitant to the down-regulation of calreticulin, protein
levels of the immature B2 receptor form of 53  4 kDa were
strongly increased (Fig. 4(a), right panel).
Similar results were obtained by RNA interference studies
under in vivo conditions by expanding two diﬀerent cell clones
with RNA polymerase II promoter-driven expression of a
micro-RNA targeting calreticulin (Fig. 4(b)). Upon three weeks
of expansion in NOD.Scid mice, micro-RNA expressing HEK
cell clones targeting calreticulin by RNA interference showed a
signiﬁcant down regulation of calreticulin expression relative to
cell clones expressing a control micro-RNA as assessed by
immunoblotting (Fig. 4(b), left panels). In agreement with the
involvement of calreticulin in B2 receptor maturation under
in vivo conditions, protein levels of the immature B2 receptor
form of 53  4 kDa were signiﬁcantly increased upon down
regulation of calreticulin (Fig. 4(b), right panel). Together these
experiments provide evidence that restoration of calreticulin
expression contributed to the enhanced B2 receptor protein
maturation of the novel in vivo model.
Fig. 2 In vivo expansion of HEK293 cells in NOD.Scid mice restores an imbalanced chaperone system. (a) HEK293 cells were subcutaneously
injected into immune-deﬁcient NOD.Scid mice. After in vivo expansion for three weeks, mice were anesthetized (upper panel), and the expanded
cell pellet was isolated (lower panel; Scid mouse-expanded HEK). (b) Microarray gene expression proﬁling of NOD.Scid-expanded (in vivo; Scid
mouse), and in vitro cultivated clonal HEK293 cells (in vitro, Cells; 450 mg/dl glucose). The heat map shows normalized signal intensity values of
the glucose-sensitive chaperones identiﬁed in Fig. 1(b). The analysis identiﬁed diﬀerentially expressed probe sets of four diﬀerent chaperones
(*P valuer0.01). Probe sets of beta actin demonstrate integrity of biotin-labeled cRNAs used for gene chip hybridization (30/50 ratio: 1.23–1.28).
The microarray data represent two biological replicates for each condition (GSE18739). Data shown are representative of three independent
experiments performed with 2–3 mice each.
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In vivo expansion of HEK293 cells in NOD.Scid mice enhances
AT1/B2 receptor heterodimerization
Eﬃcient maturation of the B2 receptor protein is required
for heterodimerization with the AT1 receptor.
10 To analyze
whether the in vivo model also supported heterodimerization
of the B2 receptor with the AT1 receptor, we expanded
HEK-AT1/B2 cells co-expressing AT1 and B2 receptors
in NOD.Scid mice. The expression of the AT1 and B2
receptor on in vivo expanded HEK cells was determined by
immunoﬂuorescence applying antibodies speciﬁcally cross-
reacting with the AT1 and B2 receptor, respectively.
3–5
Immunoﬂuorescence analysis demonstrated a high degree of
co-localization of AT1 and B2 receptors on the cell membrane
of in vivo expanded HEK-AT1/B2 cells (Fig. 5(a)).
To determine whether the co-localized receptors formed a
direct protein interaction, we enriched the AT1 receptor with
AT1-speciﬁc antibodies, and detected the co-enriched B2
receptor with B2-speciﬁc antibodies in immunoblot. As a
control, eﬃcient enrichment of AT1 was conﬁrmed by
immunoblotting with AT1-speciﬁc antibodies. Enrichment of
AT1 receptors with AT1-speciﬁc antibodies and detection of
co-enriched B2 receptors in immunoblot revealed the direct
interaction of AT1 with B2 receptors on NOD.Scid-expanded
HEK-AT1/B2 cells (Fig. 5(b)). Thus, the mature B2 receptor
protein of in vivo expanded cells undergoes a direct interaction
with the AT1 receptor, which is a characteristic feature of
receptor hetero(di)merization.2–5,10
Assessment of AT1/B2 receptor function in vivo by drug
treatment with the AT1-speciﬁc antagonist losartan
Do the AT1/B2 receptor complexes of in vivo expanded
HEK-AT1/B2 cells display functional features of AT1/B2
receptor heterodimers? The functional coupling of the in vivo
synthesized heterodimers was analyzed by their sensitivity to
stimulation with angiotensin II. Stimulation of AT1/B2
receptor heterodimers by angiotensin II induces receptor
co-internalization and down regulation.3,15 To assess the
stimulation of AT1/B2 receptor heterodimers in vivo, we
determined the eﬀect of circulating blood angiotensin II on
B2 receptors associated with AT1 in AT1/B2 heterodimers
relative to individual B2 receptors. To this end, NOD.Scid
mice were transplanted with HEK-AT1/B2 or HEK-B2 cells.
After cell injection, mice were treated for three weeks with a
standard dose of the AT1-speciﬁc antagonist, losartan
(30 mg kg1, supplied in drinking water), which inhibits AT1
receptor-stimulated responses in mice.16 The number of
cellular B2 receptors after three weeks of in vivo expansion
was quantiﬁed with [125I]-labeled F(ab)2 fragments of aﬃnity-
puriﬁed anti-B2 receptor antibodies. Losartan treatment of
NOD.Scid mice induced a signiﬁcant increase in the number
of B2 receptors on expanded HEK-AT1/B2 cells relative to
untreated mice (Fig. 6, columns 1, 2). For comparison, losartan
treatment did not aﬀect B2 receptor levels of NOD.Scid-expanded
HEK-B2 cells expressing only B2 receptors (Fig. 6, columns 3, 4).
As a control, in vivo expanded HEK-P3 cells without B2 receptor
expression did not show a signiﬁcant interaction with
[125I]-labeled anti-B2 receptor antibodies (Fig. 6, columns 5, 6).
Together these experiments are compatible with the notion that
B2 receptors, which are part of functional AT1/B2 receptor
heterodimers are internalized by circulating angiotensin II
activating AT1. Vice versa, inhibition of AT1 by losartan could
prevent AT1/B2 co-internalization as revealed by the increased
B2 receptor number of HEK-AT1/B2 cells isolated from
losartan-treated mice relative to untreated mice.
Altogether, the in vivo expansion of HEK cells in NOD.Scid
mice restored an imbalance of the general chaperone system
induced by conventional in vitro cell culture. As a consequence,
Fig. 3 Expansion of HEK293 cells in NOD.Scid mice facilitates B2
receptor protein maturation. (a) Immunoﬂuorescence detection of the
B2 receptor with anti-B2 receptor antibodies (anti-B2; cell nuclei
were stained with DAPI) on a cryosection of a NOD.Scid-expanded
HEK-B2 cell pellet (left panel; Scid mouse-expanded HEK-B2). As a
control, the anti-B2 receptor antibodies did not interact with expanded
HEK-P3 cells lacking B2 receptor expression (right panel; Scid mouse-
expanded HEK-P3), (original magniﬁcation, 630). (b) In vivo
expansion of two diﬀerent B2 receptor expressing HEK-B2 cell clones
for three weeks in NOD.Scid mice induced the synthesis of the
mature B2 receptor ofB67 kDa (lanes 3,4; Scid) whereas the immature
B53 kDa B2 receptor (immat. B2) was the predominant form before
in vivo expansion and cultivation in high glucose medium (lanes 1,2;
Cells). The B2 receptor was detected on enriched membranes by
immunoblot with F(ab)2 fragments of aﬃnity-puriﬁed B2-speciﬁc
antibodies pre-absorbed to human proteins (IB: anti-B2). Right
panels: Calreticulin protein expression as determined in immunoblot
with anti-calreticulin antibodies (IB: anti-Calret.) was signiﬁcantly
increased upon in vivo expansion of HEK-B2 cells in NOD.Scid mice
(upper panel; ‘‘Scid’’ versus ‘‘Cells’’). Immunoblot detection of GRP78
did not reveal a major diﬀerence between in vivo expanded relative to
conventionally cultivated cells (lower panel). (c) As a control, protein
levels and maturation of the related AT2 receptor were not diﬀerent
before and after in vivo expansion of two diﬀerent HEK-AT2 cell
clones in NOD.Scid mice as determined in immunoblot with F(ab)2
fragments of aﬃnity-puriﬁed anti-AT2 antibodies pre-absorbed to
human proteins (IB: anti-AT2). In lane ‘‘P’’, anti-AT2 antibodies
pre-absorbed to the immunizing antigen were used as a control to
conﬁrm antibody speciﬁcity.
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the novel system enabled the study of protein maturation,
heterodimerization and function of an important cardiovascular
receptor system with transfected cells under in vivo conditions.
Discussion
Hyperactivity of the angiotensin II AT1 receptor is a common
feature of cardiovascular disease.1 Cellular mechanisms
accounting for AT1 receptor sensitization in vivo are therefore
of major interest regarding the pathogenesis and therapeutic
concepts of cardiovascular disorders. Heterodimerization of
the angiotensin AT1 receptor with the bradykinin B2 receptor
leads to sensitization of the angiotensin II response in
individuals with cardiovascular risk factors.3–5 Sensitization
of the angiotensin II response relies on the formation of
covalently stabilized receptor protein complexes, which provide
a kinetically favoured platform for interaction with intra-
cellular signalling molecules relative to dissociable receptors.6,7
Fig. 4 Involvement of calreticulin in B2 receptor maturation of in vivo expanded cells. (a) Left panel: Immunoblot detection of calreticulin
(IB: anti-Calret.) in replated, NOD.Scid-expanded HEK-B2 cells transfected with a control RNAi duplex (Cont-RNAi; lane 1) or RNAi duplexes
targeting the coding sequence of calreticulin (RNAi-Calret.1/2; lanes 2,3) conﬁrms the down regulation of calreticulin by RNA interference. Right
panel: Immunoblot detection of the B2 receptor with F(ab)2 fragments of aﬃnity-puriﬁed B2-speciﬁc antibodies pre-absorbed to human proteins
(IB: anti-B2) on enriched membranes of in vivo expanded and replated HEK cells transfected with a control RNAi duplex (Cont-RNAi; lane 1) or
RNAi duplexes targeting the coding sequence of calreticulin (RNAi-Calret.1/2; lanes 2,3). Upon down regulation of calreticulin, protein levels of
the immature B2 receptor form ofB53 kDa (immat. B2) were strongly increased. (b) Similar results as in (a) were obtained under in vivo conditions
with two diﬀerent, NOD.Scid-expanded HEK-B2 cell clones expressing a control micro-RNA (Cont-RNAi; lanes 1,3), or a micro-RNA targeting
the coding sequence of calreticulin (RNAi-Calret.; lanes 2,4). Immunoblots show detection of calreticulin (IB: anti-Calret.; upper panel-left),
beta-actin (IB: anti-Actin; lower panel-left), and the B2 receptor (IB: anti-B2; right panel).
Fig. 5 In vivo expansion of HEK293 cells in NOD.Scid mice enhances AT1/B2 receptor heterodimerization. (a) Immunoﬂuorescence detection of the
B2 receptor with rabbit anti-B2 receptor antibodies and Alexa Fluor 488-labeled secondary antibodies (left panel; anti-B2), and AT1 receptor with
rat anti-AT1 receptor antibodies and Alexa Fluor 546-labeled secondary antibodies (middle panel; anti-AT1) revealed co-localization of AT1 and
B2 receptors (right panel; Colocalization AT1/B2) on dispersed HEK-AT1/B2 cells isolated after in vivo expansion for three weeks in NOD.Scid
mice (original magniﬁcation, 630). (b) Immunoblot detection of the B2 receptor (IB: anti-B2; lanes 1,2), and AT1 receptor (IB: anti-AT1;
lanes 3,4) was performed with solubilized AT1/B2 receptor expressing HEK-AT1/B2 cells expanded for three weeks in NOD.Scid mice (lanes 1,3).
In lane 2, the B2 receptor co-enriched with AT1 receptor-speciﬁc antibodies (AP: anti-AT1) was detected in immunoblot with F(ab)2 fragments of
aﬃnity-puriﬁed anti-B2 receptor antibodies pre-absorbed to human proteins. As a control, the immunoaﬃnity-enriched AT1 receptor was detected
in immunoblot with anti-AT1 antibodies (lane 4).
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However, factors, which account for the formation of
covalently associated AT1/B2 receptor heterodimers are still
not clear. Several groups showed that heterodimerization of
the B2 receptor with the angiotensin II AT1 receptor or the
closely related AT2 receptor is very eﬀective in a native
environment.2–6,17 In contrast, under in vitro conditions, B2
receptor maturation and heterodimerization can be severely
aﬀected by chosen cell and culture conditions, which may
disturb the ﬁne-tuned equilibrium of the general chaperone
system.10,18
In view of the pathophysiological importance of AT1/B2
receptor heterodimers, we sought to establish a cell system,
which enables to study that important cardiovascular receptor
system in a physiological environment. Cultured human
embryonic kidney (HEK) cells were implanted subcutaneously
into immunodeﬁcient NOD.Scid mice, and expanded in the
well-controlled physiological environment of mice. We chose
HEK cells because several scientiﬁc facts make human
embryonic kidney cells a suitable cell line for the functional
study of cardiovascular targets, and speciﬁcally the angio-
tensin II AT1 receptor. (I) Kidney cell damage is a common
feature of many cardiovascular disorders, e.g. hypertension,
atherosclerosis, diabetes, heart failure.19–21 (II) Renal cell
damage is induced by AT1 receptor stimulation and excessive
angiotensin II release in the course of cardiovascular disease.22
(III) Microarray gene expression data showed renal epithelial,
glomerular, and podocyte markers indicative of the embryonic,
renal phenotype of in vivo expanded HEK cells. In view of the
causal relationship between cardiovascular disease, renal cell
destruction and the angiotensin II system as a major player,
the human embryonic kidney cell (HEK) is capable of
revealing important aspects of angiotensin-related eﬀects on
cardiovascular disease-induced organ cell damage.
Microarray analysis was used to validate the novel in vivo
system. Microarray gene expression proﬁling revealed that the
expansion of HEK cells for three weeks in vivo in immuno-
deﬁcient NOD.Scid mice aﬀected only a small subset of
chaperones while leaving the general glucose-sensitive
chaperone system largely unaltered. Notably, there was a major
enhancement of calreticulin expression in NOD.Scid-expanded
cells relative to conventional cell culture. Thus, the in vivomodel
seemed to restore an imbalance of the general chaperone system
induced by conventional cell culture conditions.
Calreticulin is an indispensable chaperone,23,24 and maturation
of the B2 receptor protein relies on calreticulin.
10,14 In
agreement with the importance of calreticulin for the B2
receptor protein, the maturation of B2 was strongly enhanced
in the novel system. RNA interference revealed a causal
relationship between calreticulin expression and enhanced B2
receptor maturation. Concomitantly to the enhanced protein
maturation, interaction of the B2 receptor with AT1 was
strongly supported in the novel in vivo system as demonstrated
by immunoﬂuorescence and co-enrichment studies. The
AT1/B2 receptor heterodimers synthesized in HEK cells under
in vivo conditions were also functionally active, stimulated and
co-internalized by circulating angiotensin II because treatment
of NOD.Scid mice with the AT1-speciﬁc antagonist, losartan,
substantially increased the number of B2 receptors on
expanded HEK293 cells with AT1/B2 heterodimers. Thus,
the newly established system enables the study of protein
maturation and function under in vivo conditions.
In addition to the functional analysis of an important
cardiovascular receptor system, our experiments provide
strong evidence that the established model is also suitable to
study the eﬀect of drug action under in vivo conditions in
general. During cell expansion, the transplanted cells seem to
be eﬀectively connected to the vascular system of NOD.Scid
mice. As a consequence, a prototypic cardiovascular drug-
such as losartan-supplied in drinking water to NOD.Scid mice
could gain access to the proteins of expanded HEK293 cells.
Conclusions
Our study established a novel model to analyze the function of
proteins under in vivo conditions by applying immunodeﬁcient
NOD.Scid mice for in vivo expansion of cells. Using the model
we studied AT1/B2 receptor heterodimers, which is an important
cardiovascular receptor system and contributes to an exaggerated
angiotensin II response in individuals with cardiovascular
disease. With the novel model, we show that eﬃcient B2 receptor
maturation is a prerequisite for heterodimerization with the
angiotensin II AT1 receptor under in vivo conditions. Validation
of the system by microarray gene expression proﬁling revealed
restoration of an imbalanced chaperone system in the novel
in vivo cell expansion model relative to conventional cell culture.
The model also proved suitable for the study of drug action
under in vivo conditions as exempliﬁed with a widely used
cardiovascular drug, i.e. losartan.
Fig. 6 Assessment of AT1/B2 receptor function in vivo by drug
treatment with the AT1-speciﬁc antagonist losartan. The functional
coupling of AT1/B2 receptor heterodimers of in vivo expanded cells
was assessed by the sensitivity to angiotensin II stimulation. In vivo
stimulation of AT1/B2 receptors by circulating angiotensin II was
analyzed by B2 receptor quantiﬁcation of cells expanded in NOD.Scid
mice and treated with or without the AT1-speciﬁc antagonist losartan.
B2 receptors were quantiﬁed with [
125I]-labeled F(ab)2 fragments
of aﬃnity-puriﬁed anti-B2 receptor antibodies (1 mCi/point; ﬁnal
concentration 5  108 M) on dispersed NOD.Scid mouse-expanded
HEK cells expressing either AT1/B2 (columns 1,2; AT1/B2) or B2
receptor only (columns 3,4; B2). As a control, the binding assay was
performed with in vivo expanded HEK-P3 cells without B2 receptor
expression (columns 5,6; P3). HEK cells were isolated after in vivo
expansion in NOD.Scid mice treated without () or with (+) losartan
for three weeks (30 mg kg1) as indicated. Three individual experiments
were done in triplicate each. The data represent mean S.E., *, Po 0.03.
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